Skip to main content


Keep up to date with the latest news and developments about our projects, studies, and trials.



8 August 2022 – New publication makes the case for Perpetual Observational Studies (POS): A team of infectious disease experts introduce a novel concept that has the potential to improve clinical research.

11 July 2022 – A multi-country study of monkeypox being launched – first cases enrolled in Geneva: We are part of yet another initiative aimed at tackling the monkeypox outbreak.

7 July 2022 – European response to monkeypox virus outbreak: Ecraid is assessing its readiness to respond in the event the monkeypox outbreak spreads further in Europe.

29 April 2022 – Ecraid brought insights and expertise to ECCMID 2022: This was the first time that Ecraid as a foundation took part in the prestigious congress organised by the European Society of Clinical Microbiology & Infectious Diseases (ESCMID). 

PUBLICATION: The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations, The Lancet Infectious Diseases.


Thinking outside the box with Ana C. Hernandez
Ecraid introduces new COO Nils Visser
Ecraid is an official entity
ECRAID-Prime launches December first
Ecraid officially launched to tackle infectious disease



Ecraid is proud to announce ECRAID-Prime, a new Primary care adaptive platform trial for pandemics and epidemics. The project will focus on desperately needed, evidence-based therapeutics for use in primary care. This will have the potential for considerable reach and impact on individual suffering and functioning, as well as on the sustainability of health services. ECRAID-Prime, a European Adaptive Platform Trial (APT) of COVID-19 therapeutics in primary care will build on many years of EU investment in infrastructure for primary care trials and a mature primary care research network that has pioneered novel, efficient, platform clinical trial designs.


ECRAID-Base e-learning platform

Officially opened on 10 November 2021, the ECRAID-Base e-learning platform is now available. The open access “Emerging infectious diseases and antimicrobial resistance: diagnostics, treatments, vaccines and other preventive and/or therapeutic interventions” postgraduate course includes webinars and papers by Maurizio Sanguinetti, Burcu Isler, Tobias Welte and Rosario Menendez Villanueva. The course was jointly organised by ERS and ESCMID and took place on 14 October 2021.

How clinical trials inform antibiotic stewardship is the next webinar scheduled for 19 January 2022. Register here.

Ecraid launch

Ecraid, the European Clinical Research Alliance for Infectious Diseases, officially on 14 September 2021. Over two days, 160+ people attended an online event to learn about Ecraid and the work it is doing to advance clinical research in the field of infectious diseases. Read this overview to see how the day unfolded and what our 16 presenters revealed.


Over half a million COVID-19 patient records reached

ISARIC (International Severe Acute Respiratory and Emerging Infection Consortium), one of Ecraid's non-financial partners, celebrated a milestone recently: their clinical data platform surpassed half a million COVID-19 patient records, crucial for advancing knowledge on infectious disease pandemics. As with Ecraid, ISARIC takes a collaborative approach and champions the use of pre-prepared research tools, global collaboration, and research-ready clinical networks. You can read the full press release on ISARIC’s site.